search
Back to results

Open Label Clinical Trial of Vascanox® HP on Nitric Oxide and Blood Pressure

Primary Purpose

Hypertension, Elevated Blood Pressure

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Vascanox® HP
Sponsored by
Calroy Health Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Hypertension focused on measuring hypertension, elevated blood pressure, nitric oxide, S-allylcysteine, dietary nitrate, Vascanox HP

Eligibility Criteria

25 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Mild hypertension defined as brachial artery blood pressure greater than or equal to 130 mm Hg systolic and less than or equal to 140 mm Hg systolic or greater than or equal to 85 mm Hg diastolic or less than 90 mm Hg diastolic while taking or not taking antihypertensive drugs. Not currently taking nitric oxide supplements, and not consuming nitric oxide supplements for 14 days prior to screening. Ability to give written informed consent. Ability to adhere to study protocol directives and procedures. Exclusion Criteria: Initiated or had a dose change of an antihypertensive agent less than 6 months prior to the enrollment date. A positive nitric oxide saliva test strip (result >2) on the day of Screening. A positive nitric oxide saliva test strip (result >2) on the day of Baseline/Visit 1. A high saliva NO3 test strip result (result >2) but a low NO test strip result. Current use of antibiotics. Chronic steroid use >15 mg daily. Previous myocardial infarction less than 2 years of enrollment date. Unstable angina. Previous stroke or transient ischemic attack (TIA) less than 2 years of enrollment date. Uncompensated congestive heart failure (CHF). Previous percutaneous transluminal coronary angioplasty (PTCA) or stent less than 2 years of enrollment date. Previous coronary arterial bypass graft (CABG) less than 2 years of enrollment date. Known or previous cancer less than 5 years of enrollment date. Type 1 diabetes mellitus. Prescribed dosing with insulin, injectable or inhaled. Pregnant females. Females of child bearing age not on an accepted contraception control method. Allergy/sensitivity to study products or their ingredients. Current drug or alcohol use or dependence that, in the opinion of the principal investigator, would interfere with adherence to study requirements. Inability or unwillingness of individual to give written informed consent. Current or past participation within 30 calendar days in another clinical trial, as warranted by the administration of this intervention.

Sites / Locations

  • The Hypertension Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Vascanox® HP

Arm Description

Outcomes

Primary Outcome Measures

Blood pressure
Change in blood pressure in millimeters of mercury (mmHg) assessed in the branchial artery

Secondary Outcome Measures

Salivary nitric oxide
Salivary levels of nitric oxide assessed using commercially available FDA registered strips. Nitric oxide test strips measure nitrite, which is used as an established surrogate marker for nitric oxide.

Full Information

First Posted
June 26, 2023
Last Updated
July 31, 2023
Sponsor
Calroy Health Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT05928676
Brief Title
Open Label Clinical Trial of Vascanox® HP on Nitric Oxide and Blood Pressure
Official Title
Effects of S-allylcysteine-rich Garlic Extract and Dietary Inorganic Nitrate Formula (Vascanox® HP) on Blood Pressure and Nitric Oxide Levels: an Open-label Clinical Trial Among Hypertensive Adults
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
June 24, 2023 (Actual)
Primary Completion Date
July 31, 2023 (Actual)
Study Completion Date
July 31, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Calroy Health Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Conversion of dietary nitrates to nitric oxide (NO) is a non-canonical pathway that plays an important role in NO biology, particulalry under pathological conditions. Nitrate supplementation has been shown to help control mild hypertension. Recent studies have suggested that another gaseous transmitter, hydrogen sulfide, also influences NO biosynthesis and metabolism. This open-label clinical trial will evalute the effect of Vascanox® HP, a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide, on nitric oxide bioavailability and on blood pressure in subjects experiencing elevated blood pressure. Participants will supplement with Vascanox® HP for four weeks. Blood pressure will be measured at baseline, two weeks, and fours weeks. Salivary nitric oxide will be assessed prior to and two, six, and 24 hours after dosing on the first day of the study and prior to and two hours after dosing at subsequent study visits. Participants will also self-monitor their saliva nitric oxide levels and blood pressure daily for 4 weeks. Changes in study outcomes over time will be evaluated via analysis of variance (ANOVA) and paired t-tests.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Elevated Blood Pressure
Keywords
hypertension, elevated blood pressure, nitric oxide, S-allylcysteine, dietary nitrate, Vascanox HP

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vascanox® HP
Arm Type
Experimental
Intervention Type
Dietary Supplement
Intervention Name(s)
Vascanox® HP
Intervention Description
Vascanox® HP is a proprietary formulation that combines dietary sources of nitric oxide and hydrogen sulfide aimed at increasing the levels and duration of nitric oxide biosynthesis. Vascanox® HP contains an advanced blend of berry extracts in addition to beet root powder, black garlic, vitamin C, and minerals known to influence nitric oxide biosynthesis and metabolism. Because of the particular combination of ingredients, Vascanox® HP is expected to affect both canonical and non-canonical pathways of nitric oxide production and to augment nitric oxide reservoir in the body leading to an increased and prolonged nitric oxide bioavailability.
Primary Outcome Measure Information:
Title
Blood pressure
Description
Change in blood pressure in millimeters of mercury (mmHg) assessed in the branchial artery
Time Frame
Assessed at baseline, at 2 weeks, and at the 4 week conclusion of study
Secondary Outcome Measure Information:
Title
Salivary nitric oxide
Description
Salivary levels of nitric oxide assessed using commercially available FDA registered strips. Nitric oxide test strips measure nitrite, which is used as an established surrogate marker for nitric oxide.
Time Frame
Salivary nitric oxide assessed prior to and two hours after dosing at baseline, 2 weeks, and at the 4 week conclusion of the study. Salivary nitric oxide will be additionally assessed at 6 and 24 hours after dosing on the first day of the study only.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Mild hypertension defined as brachial artery blood pressure greater than or equal to 130 mm Hg systolic and less than or equal to 140 mm Hg systolic or greater than or equal to 85 mm Hg diastolic or less than 90 mm Hg diastolic while taking or not taking antihypertensive drugs. Not currently taking nitric oxide supplements, and not consuming nitric oxide supplements for 14 days prior to screening. Ability to give written informed consent. Ability to adhere to study protocol directives and procedures. Exclusion Criteria: Initiated or had a dose change of an antihypertensive agent less than 6 months prior to the enrollment date. A positive nitric oxide saliva test strip (result >2) on the day of Screening. A positive nitric oxide saliva test strip (result >2) on the day of Baseline/Visit 1. A high saliva NO3 test strip result (result >2) but a low NO test strip result. Current use of antibiotics. Chronic steroid use >15 mg daily. Previous myocardial infarction less than 2 years of enrollment date. Unstable angina. Previous stroke or transient ischemic attack (TIA) less than 2 years of enrollment date. Uncompensated congestive heart failure (CHF). Previous percutaneous transluminal coronary angioplasty (PTCA) or stent less than 2 years of enrollment date. Previous coronary arterial bypass graft (CABG) less than 2 years of enrollment date. Known or previous cancer less than 5 years of enrollment date. Type 1 diabetes mellitus. Prescribed dosing with insulin, injectable or inhaled. Pregnant females. Females of child bearing age not on an accepted contraception control method. Allergy/sensitivity to study products or their ingredients. Current drug or alcohol use or dependence that, in the opinion of the principal investigator, would interfere with adherence to study requirements. Inability or unwillingness of individual to give written informed consent. Current or past participation within 30 calendar days in another clinical trial, as warranted by the administration of this intervention.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Houston, M.D.
Organizational Affiliation
The Hypertension Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Hypertension Institute
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37205
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Open Label Clinical Trial of Vascanox® HP on Nitric Oxide and Blood Pressure

We'll reach out to this number within 24 hrs